← Oncology Approval Tracker

FDA DECISION ·

Verzenio + endocrine therapy

abemaciclib + tamoxifen or an aromatase inhibitor · Eli Lilly

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment for adults with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. This action removed the prior Ki-67 testing requirement.

LAMPGEN ANALYSIS

Why it matters

The approval broadened access to qualifying high-risk patients without a Ki-67 result.

What research teams should watch

Apply nodal and clinicopathologic high-risk criteria rather than the older Ki-67 threshold.

PRIMARY RECORDS

Sources